Evaluation of prostate specific antigen in the prognosis of patients with advanced prostate cancer

Evaluation of prostate specific antigen in the prognosis of patients with advanced prostate cancer

OBJECTIVE: To evaluate the survival rate of patients with advanced prostate cancer in a univariate form, according to the preoperative and first postoperative determination of PSA levels. MATERIALS AND METHODS: From February 1987 to June 1995, 92 patients were submitted to maximum blockage androgen...

Full description

Bibliographic Details
Main Authors:	Francisco Paulo da Fonseca, Ademar Lopes, Walter Antonio Melarato Jr., Wilson Bachega Jr., Osvaldo Junior Batista Marques, Raimunda Nonata Pereira
Format:	Article
Language:	English
Published:	Associação Paulista de Medicina
Series:	São Paulo Medical Journal
Subjects:	PSA Advanced prostate cancer Maximum blockage androgen Prognostic factors
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31801998000500003&lng=en&tlng=en

Similar Items

Prognostic significance of Prostate-Specific Antigen (PSA) rate of change in patients with advanced prostate cancer
by: A E Aghaji, et al.
Published: (2005-01-01)

Role of maximum androgen blockade in advanced prostate cancer
by: Rajinikanth Ayyathurai, et al.
Published: (2009-01-01)

The Accuracy of Increased Blood Concentration of Prostate-Specific Antigen to Prostate Malignancy
by: Daniel Mahendra Krisna, et al.
Published: (2018-04-01)

Comparison of two adjuvant hormone therapy regimens in patients with high-risk localized prostate cancer after radical prostatectomy: primary results of study CU1005
by: Kun Chang, et al.
Published: (2016-01-01)

Prostate – Specific Antigen (Psa) as a Screening Tool for Benign Prostate Hyperplasia (Bph) and Prostate Cancer (Pca) in Sulaimani Province
by: Sirwan M. Muhammad, et al.
Published: (2013-09-01)

Kinetics of Prostate-Specific Antigen after Carbon Ion Radiotherapy for Prostate Cancer
by: Narisa Dewi Maulany Darwis, et al.
Published: (2020-03-01)

Molecular Detection of Prostate Specific Antigen in Patients with Prostate Cancer or Benign Prostate Hyperplasia the First Investigation from Iran
by: L Andonian, et al.
Published: (2005-08-01)

Molecular Detection of Prostate Specific Antigen in Patients with Prostate Cancer or Benign Prostate Hyperplasia the First Investigation from Iran
by: L Andonian, et al.
Published: (2005-09-01)

Hormonal therapy in metastatic prostate cancer: current perspectives and controversies
by: Manish Garg, et al.
Published: (2013-09-01)

Prostate Specific Antigen Levels Among Men With Prostate Cancer in Ramadi City
by: Jalil Ibrahim Salih, et al.
Published: (2013-08-01)

Maximal androgen blockade for advanced prostate cancer
by: Rajiv Paul Mukha, et al.
Published: (2010-01-01)

Effect of urinary retention on the levels of prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) in prostatic disease
by: R Chawla, et al.
Published: (2003-01-01)

Evaluation of the Cure about the Prostate Cancer Patients, Taking Radiothraphy According To the Result of the Prosecution Prostate Specific Antigen
by: Feryal Karaca, et al.
Published: (2018-10-01)

Prostate Specific Antigen. Current clinical application and future prospects
by: Katerina Duskova, et al.
Published: (2015-03-01)

Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT
by: Zeina Ayoub, et al.
Published: (2022-12-01)

Utility of Prostate-Specific Antigen Isoforms and Prostate Health Index in the Diagnosis of Metastatic Prostate Cancer
by: Govinda Nanjaiah Laxmana Raju, et al.
Published: (2023-06-01)

The Novel Function of Unsymmetrical Chiral CCN Pincer Nickel Complexes as Chemotherapeutic Agents Targeting Prostate Cancer Cells
by: Jing-Jing Qu, et al.
Published: (2022-05-01)

Investigation of prostate specific antigen glycosylation
by: Marinović Vesna, et al.
Published: (2000-01-01)

Comparison of changes in serum prostate specific antigen in prostate cancer patients treated either with flutamide or stilboestrol monotherapy
by: O F Otobo, et al.
Published: (2020-01-01)

Serum prostate specific antigen is a good indicator of prostatic volume in men with benign prostatic hyperplasia
by: Ebenezer Abotsi, et al.
Published: (2022-12-01)

Serum total prostate-specific antigen values in men with symptomatic prostate enlargement in Nigeria: role in clinical decision-making
by: Nnabugwu II, et al.
Published: (2014-12-01)

Prostate tumor markers: diagnosis, prognosis and management
by: Gabriela Kniphoff da Silva Lawisch, et al.
Published: (2024-02-01)

Association between preoperative prostate-specific antigen levels and mortality in high- and intermediate-grade prostate cancer patients who received radical prostatectomy: Findings from the SEER database
by: Joshua Ikuemonisan, et al.
Published: (2021-06-01)

Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?
by: Shaan Kataria, et al.
Published: (2017-07-01)

Predictors of survival outcomes in native sub Saharan black men newly diagnosed with metastatic prostate cancer
by: Jibril Oyekunle Bello
Published: (2017-05-01)

Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer
by: Taizo Uchimoto, et al.
Published: (2021-01-01)

Prostate-specific antigen kinetics and metastasis-free survival in patients treated with external beam radiotherapy combined with high-dose-rate brachytherapy boost and androgen deprivation therapy for localized prostate cancer
by: Marcin Miszczyk, et al.
Published: (2022-02-01)

Clinical Implications of Nadir Serum Prostate-Specific Antigen Levels After Transurethral Enucleation of the Prostate
by: Yung-Ting Cheng, et al.
Published: (2022-07-01)

Adaptive sequential plan-on-plan optimization during prostate-specific antigen response guided radiotherapy of recurrent prostate cancer
by: Vilberg Jóhannesson, et al.
Published: (2021-04-01)

Evaluation of prostate-specific antigen testing: An empirical survey of laboratories in Nigerian tertiary care centers
by: Ijeoma A Meka, et al.
Published: (2022-01-01)

The Current Status of Prostate Cancer*
by: Mukund S. Joshi
Published: (2018-10-01)

Study of prostate-specific antigen levels during salvage radiotherapy after prostate cancer surgery
by: Takuya Aizawa, et al.
Published: (2023-10-01)

Validating fPSA Glycoprofile as a Prostate Cancer Biomarker to Avoid Unnecessary Biopsies and Re-Biopsies
by: Tomas Bertok, et al.
Published: (2020-10-01)

Parameters predicting for prostate specific antigen response rates at one year post low-dose-rate intraoperative prostate brachytherapy
by: Kevin Martell, et al.
Published: (2017-04-01)

The Predictive Role of Prostate-Specific Antigen Changes Following Transurethral Resection of the Prostate for Patients with Localized Prostate Cancer
by: Chun-Te Wu, et al.
Published: (2020-12-01)

Investigation of the Interobserver Variability of the Prostate Imaging for Recurrence Reporting (PI-RR) Score in Evaluating Local Recurrence in Prostate Cancer After Radiotherapy: Are Tumor Size and Prostate-specific Antigen Important?
by: Hüseyin Akkaya, et al.
Published: (2023-04-01)

Prostate specific antigen and acinar density: a new dimension, the “Prostatocrit”
by: Simon Robinson, et al.

Application and optimization of prostate-specific antigen screening strategy in the diagnosis of prostate cancer: a systematic review
by: Zhengchao Zhang, et al.
Published: (2024-01-01)

Dynamic changes in PSA levels predict prognostic outcomes in prostate cancer patients undergoing androgen -deprivation therapy: A multicenter retrospective analysis
by: Mingqiu Hu, et al.
Published: (2023-02-01)

Prognosis of prostate gland morphology study using artificial neural network
by: Popkov V.M., et al.
Published: (2014-06-01)